MAP2K1 and familial pancreatic carcinoma: We found inhibitors such as Pimasertib (AS-703026; MEK1/2 inhibitor), Trametinib (GSK1120212; MEK1/2 inhibitor), Apitolisib (GDC-0980, Class I PI3K and mTOR inhibitor), Torkinib (PP242, mTOR inhibitor), and LY29002 (broad-spectrum inhibitor of PI3K) had a modest effect in naïve MiaPaCa2 or HPAF-II pancreatic cancer cells (i.e., at baseline), as reported31,38.